FDA Refuse to Receive: Causes, Prevention, and Response
A refuse to receive (RTR) is FDA's determination that a submitted application is so incomplete that it cannot even enter the filing review process. Unlike a refuse to file (RTF), which occurs after a substantive filing review, an RTR happens at the intake stage when basic technical completeness criteria are not met. RTR decisions are most common with ANDAs but also apply to NDAs and BLAs. Prevention starts with thorough pre-submission validation and, for complex applications, a pre-submission (Type B) meeting.
Key Takeaways
Key Takeaways
- RTR occurs at intake for basic technical incompleteness; RTF occurs after substantive filing review around Day 60
- ANDAs have historically higher RTR rates than NDAs due to more granular OGD-specific RTR criteria
- Common RTR triggers include missing eCTD modules, unpaid PDUFA/GDUFA fees, absent Form 356h, and technical validation failures
- Pre-submission eCTD validation and internal readiness reviews are the most effective RTR prevention strategies
- An RTR does not count as a review cycle; resubmission is treated as a new original application with a new PDUFA date
- An FDA refuse to receive decision stops your application before it even begins the review process. The application is returned without entering the queue for scientific evaluation. For sponsors who have invested months or years preparing a submission, an RTR represents a preventable setback that costs time, money, and credibility.
- Understanding the distinction between RTR and RTF, the technical completeness criteria FDA applies, and the differences between NDA and ANDA RTR processes is essential for regulatory professionals preparing any type of marketing application.
- In this guide, you will learn:
- The difference between refuse to receive (RTR) and refuse to file (RTF)
- Technical completeness criteria FDA applies at the intake stage
- Common reasons for RTR decisions across application types
- Specific RTR considerations for ANDAs vs NDAs/BLAs
- How to prevent RTR with pre-submission validation and meetings
- The response and resubmission process after an RTR
- ---
RTR vs RTF: A Critical Distinction
Refuse to receive and refuse to file are fundamentally different regulatory actions that occur at different stages of the application lifecycle.
A refuse to receive (RTR) is FDA's determination at initial intake that an application lacks the basic technical elements required for filing review. The application is returned to the sponsor without entering the filing review process. A [refuse to file (RTF)](/blog/refuse-to-file-prevention-guide) occurs later, after FDA has conducted a substantive filing review (typically by Day 60 for NDAs/BLAs) and determined that the application is not sufficiently complete to permit a substantive review.
Side-by-Side Comparison
| Attribute | Refuse to Receive (RTR) | Refuse to File (RTF) |
|---|---|---|
| When it occurs | At initial intake/receipt | After filing review (Day 60 for NDA/BLA) |
| What FDA evaluates | Basic technical completeness; presence of required sections and documents | Substantive completeness; adequacy of data to support review |
| Regulatory basis (NDA) | 21 CFR 314.101(a); FDA guidance on completeness | 21 CFR 314.101(d); FDA Refuse to File guidance |
| Regulatory basis (ANDA) | 21 CFR 314.101(a); ANDA-specific RTR guidance | 21 CFR 314.101(d); less common for ANDAs |
| Review effort by FDA | Minimal; checklist-based assessment | Substantive; involves review team evaluation |
| Sponsor notification | RTR letter with deficiency list | Day 74 letter (RTF decision communicated ~Day 74) |
| Impact on review clock | Clock never starts; no PDUFA date assigned | Clock stops; PDUFA date is voided |
| Resubmission | Treated as a new submission with new PDUFA date | Treated as a new submission with new PDUFA date |
An RTR is often more frustrating than an RTF because it typically results from administrative or technical failures rather than scientific deficiencies. The application may contain excellent science but fail on a missing form, incorrect format, or absent required section.
Technical Completeness Criteria
What FDA Checks at Intake
When FDA receives a marketing application, the Office of Pharmaceutical Quality and relevant review divisions perform a preliminary assessment of technical completeness before accepting the application for filing review.
For NDAs (21 CFR 314.50) and BLAs (21 CFR 601.2), the initial completeness check looks for:
| Required Element | Regulatory Basis | Common RTR Trigger |
|---|---|---|
| Application form (FDA Form 356h) | 21 CFR 314.50(a) | Missing form, unsigned, incorrect form version |
| Index | 21 CFR 314.50(b) | Missing or incomplete index |
| Summary documents (Module 2) | 21 CFR 314.50(c) | Missing Module 2 summaries or overviews |
| Technical sections (Modules 3-5) | 21 CFR 314.50(d) | Missing entire modules or critical subsections |
| Samples and labeling | 21 CFR 314.50(e) | Missing proposed labeling |
| Patent information | 21 CFR 314.50(h) | Missing or incomplete patent certification |
| User fee payment | PDUFA; 21 CFR 314.50 | Non-payment or insufficient PDUFA fee |
| eCTD format compliance | FDA Electronic Submissions Guidance | Non-eCTD format, technical validation failures |
| Environmental assessment or claim of categorical exclusion | 21 CFR Part 25 (specifically 25.31 for drugs, 25.32 for biologics) | Missing environmental documentation |
ANDA-Specific Completeness Criteria
For Abbreviated New Drug Applications (ANDAs), FDA applies additional RTR criteria outlined in the guidance "Abbreviated New Drug Application (ANDA): Refuse-to-Receive Standards" (most recently revised). ANDA RTR criteria are more granular because ANDAs have a more standardized structure.
ANDA-specific RTR triggers include:
| Element | RTR Trigger |
|---|---|
| Bioequivalence (BE) study | Missing BE study data or protocol when required; inadequate demonstration of pharmaceutical equivalence |
| Reference Listed Drug (RLD) | Incorrect RLD selection; missing suitability petition for non-standard RLD |
| Paragraph IV certification | Incomplete or missing patent certifications under 21 CFR 314.94(a)(12) |
| Labeling comparison | Missing side-by-side labeling comparison with RLD |
| Drug Master File (DMF) | Referenced DMF not available or not authorized for FDA review |
| Dissolution data | Missing comparative dissolution profiles |
| Inactive ingredient justification | Qualitative or quantitative differences from RLD without adequate justification |
Common RTR Reasons by Application Type
NDA RTR Reasons
| Reason | Description | Prevention |
|---|---|---|
| Missing eCTD modules | Entire modules or required sections absent from submission | Pre-submission eCTD validation against FDA technical specifications |
| PDUFA fee not paid | User fee not received before or at time of submission | Submit fee payment and confirmation before or with application |
| Missing FDA Form 356h | Unsigned or absent application form | Include signed form in Module 1 |
| Technical validation failures | eCTD fails FDA gateway validation (XML errors, file naming, structure) | Run full validation suite before submission |
| Missing patent information | Patent certification or patent information missing | Complete Section 3.2.P.1 and relevant Module 1 patent forms |
| Incomplete labeling | Proposed prescribing information absent or in wrong format | Include draft labeling in Module 1.14 in SPL format |
ANDA RTR Reasons
ANDAs have historically higher RTR rates than NDAs. FDA's Office of Generic Drugs (OGD) issues refuse-to-receive decisions more frequently because the ANDA-specific RTR guidance sets a detailed checklist.
| Reason | Frequency | Description |
|---|---|---|
| Bioequivalence data deficiencies | High | Missing or incomplete BE study report, wrong study design for the dosage form |
| Incorrect RLD | Medium | Reference product selection inconsistent with Orange Book listing |
| DMF authorization issues | Medium | Drug Master File not authorized or letter of access not provided |
| Missing comparative dissolution | Medium | Required dissolution profiles absent or using wrong methodology |
| Labeling discrepancies | Medium | Significant deviations from RLD labeling without justification |
| Patent certification errors | Medium | Incomplete Paragraph IV certifications, missing notification to patent holder |
| Formulation differences | Lower | Qualitative or quantitative inactive ingredient differences exceeding SUPAC thresholds without justification |
FDA publishes quarterly metrics on ANDA refuse-to-receive rates. These rates have fluctuated significantly since GDUFA implementation. Monitoring these metrics helps calibrate your quality assurance process for ANDA submissions. As of recent FDA reporting, ANDA RTR rates have been in the 5-10% range, though this varies by dosage form complexity.
Pre-Submission Strategies to Prevent RTR
Strategy 1: Pre-Submission Meeting (Type B)
For NDAs and BLAs, a pre-submission (Type B) meeting with the review division allows sponsors to discuss:
- Whether the application contains all required components
- Specific data formatting expectations
- Any unusual circumstances that might affect filing
For ANDAs, sponsors can request a pre-submission teleconference with OGD to discuss anticipated completeness issues.
Strategy 2: Comprehensive eCTD Validation
Technical validation failures are among the most preventable RTR causes. Before submitting, validate your eCTD against:
| Validation Level | What It Checks | Tools |
|---|---|---|
| XML schema validation | eCTD backbone structure, DTD compliance | eCTD validation software |
| Regional validation | FDA-specific regional rules (US Regional DTD) | FDA-specific validation tools |
| File-level validation | PDF specifications, file naming, hyperlinks, bookmarks | Document QC tools |
| Content completeness | All required sections populated, cross-references valid | Manual review + validation tools |
| Gateway validation | Simulates FDA Electronic Submissions Gateway checks | FDA ESG test environment |
Strategy 3: Internal Readiness Review
Before submission, conduct an internal readiness review against:
- FDA Form 356h checklist - Every field completed, form signed by authorized representative
- Module-by-module inventory - Verify every required section is populated
- eCTD lifecycle check - Confirm sequence numbering, operation attributes, and document references
- User fee confirmation - Verify PDUFA/GDUFA fee payment receipt
- Patent and exclusivity review - Confirm all certifications are complete and accurate
Strategy 4: Use FDA's Pre-Submission Checklist
FDA publishes application filing checklists for different application types. These checklists mirror the criteria FDA's intake team applies:
| Application Type | Relevant FDA Checklist/Guidance |
|---|---|
| NDA | "Filing Review Checklist" in NDA Filing Review guidance |
| BLA | BLA filing review criteria in applicable CBER/CDER guidance |
| ANDA | "ANDA Refuse-to-Receive Standards" guidance |
| 505(b)(2) | Same as NDA; additional considerations for reliance on listed drug data |
Response and Resubmission After an RTR
What Happens After an RTR Decision
When FDA issues an RTR:
- FDA sends an RTR letter listing the specific deficiencies that triggered the decision
- The application is not filed and no PDUFA date is assigned
- The submission is returned to the sponsor (electronically, the application is not processed further)
- No review clock starts - the RTR application is treated as if it was never received for review purposes
Resubmission Process
| Step | Action | Timeline Consideration |
|---|---|---|
| 1. Review RTR letter | Identify every deficiency cited | Immediately upon receipt |
| 2. Remediate deficiencies | Correct all cited issues; validate corrections | Depends on deficiency complexity |
| 3. Resubmit as new application | The resubmission is treated as a new original application | New PDUFA date assigned from resubmission date |
| 4. New user fee | A new PDUFA/GDUFA fee may be required if the original fee was refunded | Confirm with FDA finance |
| 5. New filing review | FDA conducts a fresh filing review on the resubmission | Standard filing review timelines apply |
Unlike a refuse to file (RTF), where sponsors sometimes request a Type A meeting to discuss the RTF decision, RTR decisions are typically straightforward technical completeness failures. A meeting is rarely necessary. Instead, focus on fixing the cited deficiencies and resubmitting as quickly as possible.
RTR vs RTF Resubmission Differences
| Attribute | After RTR | After RTF |
|---|---|---|
| Resubmission type | New original application | New original application |
| User fee | May need new payment | May need new payment |
| Filing review | Full filing review conducted | Full filing review conducted |
| Can prior submission be referenced | Limited; application was never filed | Limited; depends on what was retained |
| Typical resubmission timeline | Weeks (if only technical fixes needed) | Months (substantive deficiencies to address) |
ANDA vs NDA RTR Differences
The RTR process differs meaningfully between NDAs and ANDAs due to different regulatory frameworks and review division practices.
Key Differences
| Dimension | NDA/BLA RTR | ANDA RTR |
|---|---|---|
| Governing guidance | 21 CFR 314.101(a); general NDA filing requirements | ANDA-specific RTR guidance (OGD) |
| RTR rate | Lower (NDAs are typically more carefully prepared) | Higher (more granular RTR criteria, higher volume) |
| Common causes | Missing modules, eCTD technical failures, fee issues | BE data deficiencies, DMF issues, RLD errors |
| Pre-submission meeting | Type B meeting with review division | Pre-submission teleconference with OGD |
| Review division | CDER review division or CBER | Office of Generic Drugs (OGD) |
| User fee | PDUFA | GDUFA |
ANDA-Specific RTR Guidance Updates
FDA's Office of Generic Drugs periodically updates its RTR standards. The guidance "ANDA Submissions - Refuse-to-Receive Standards" has been revised multiple times since its initial publication. Each revision may add, modify, or remove RTR criteria. Regulatory professionals preparing ANDA submissions should:
- Check for the most current version of the RTR guidance before submission
- Review FDA's Generic Drug Program regulatory science initiatives for upcoming changes
- Monitor FDA's ANDA filing metrics published in GDUFA performance reports
Key Regulatory References
| Document | Relevance |
|---|---|
| 21 CFR 314.101(a) | General provisions for NDA/ANDA filing; basis for RTR |
| 21 CFR 314.50 | NDA content and format requirements |
| 21 CFR 314.94 | ANDA content and format requirements |
| 21 CFR 601.2 | BLA content and format requirements |
| FDA Guidance: "ANDA Submissions — Refuse-to-Receive Standards" | ANDA-specific RTR criteria |
| FDA Guidance: "Providing Regulatory Submissions in Electronic Format — eCTD Specifications" | eCTD technical requirements |
| PDUFA VII / GDUFA III Commitment Letters | User fee and review timeline requirements |
| FDA Guidance: "Formal Meetings Between the FDA and Sponsors or Applicants" | Pre-submission meeting procedures |
Is an RTR the same as a refuse to file?
No. An RTR occurs at the intake stage before filing review begins, based on basic technical completeness. An RTF occurs after FDA conducts a substantive filing review (typically by Day 60) and determines the application is insufficient for substantive review. RTR is earlier and based on more fundamental deficiencies.
Can I appeal an RTR decision?
RTR decisions are generally not appealed because they are based on objective technical completeness criteria. If you believe the RTR was issued in error, you can contact the review division to discuss, but the typical path is to fix the deficiencies and resubmit.
Does an RTR count as a "cycle" for my application?
No. Because the application was never filed, an RTR does not constitute a review cycle. The resubmission is treated as a new original application.
How long does it take FDA to issue an RTR?
RTR decisions are typically made within days to weeks of receipt, depending on the application type and FDA workload. For ANDAs, OGD targets RTR decisions within 60 days of receipt per GDUFA commitments.
Is my user fee refunded after an RTR?
Under PDUFA, user fees are generally refunded if the application is refused before filing. Under GDUFA, fee refund policies differ. Check the applicable user fee provisions and contact FDA's fee management staff.
Can I submit a pre-IND meeting package to prevent RTR of my eventual NDA?
Pre-IND meetings (Type B) address IND-stage questions. For NDA filing prevention, request a pre-NDA (Type B) meeting specifically to discuss application completeness and filing strategy.